The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the first-line setting for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Randomized trials have demonstrated similar and significant improvements in progression-free survival u...

Descripción completa

Detalles Bibliográficos
Autores principales: Grinshpun, Albert, Tolaney, Sara M., Burstein, Harold J., Jeselsohn, Rinath, Mayer, Erica L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033931/
https://www.ncbi.nlm.nih.gov/pubmed/36949066
http://dx.doi.org/10.1038/s41523-023-00520-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033931/
https://www.ncbi.nlm.nih.gov/pubmed/36949066
http://dx.doi.org/10.1038/s41523-023-00520-7

Ejemplares similares